Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03736473 | A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients | PHASE1 | COMPLETED | 6 | — | — | Nov 7, 2018 | Jun 19, 2019 | Jul 8, 2019 | 1 | Japan |
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for MEDI9447
| Arm | Type | Description |
|---|---|---|
| MEDI9447 monotherapy | OTHER | Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies |
| Name | Type | Description |
|---|---|---|
| MEDI9447 (oleclumab) | DRUG | MEDI9447 administered intravenously |
Major Inclusion Criteria: * Adult subjects; age ≥ 20 years * Has a histologically confirmed solid malignancy that is refractory to standard therapy or for which no standard of care regimen currently exists * Subjects must have at least 1 lesion that is measureable using RECIST v1.1 * All subjects m...